SPRO
Price
$2.50
Change
-$0.06 (-2.34%)
Updated
Jun 6 closing price
Capitalization
139.78M
59 days until earnings call
XENE
Price
$31.64
Change
+$0.91 (+2.96%)
Updated
Jun 6 closing price
Capitalization
2.43B
59 days until earnings call
Interact to see
Advertisement

SPRO vs XENE

Header iconSPRO vs XENE Comparison
Open Charts SPRO vs XENEBanner chart's image
Spero Therapeutics
Price$2.50
Change-$0.06 (-2.34%)
Volume$2.55M
Capitalization139.78M
Xenon Pharmaceuticals
Price$31.64
Change+$0.91 (+2.96%)
Volume$576.17K
Capitalization2.43B
SPRO vs XENE Comparison Chart
Loading...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SPRO vs. XENE commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SPRO is a Buy and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (SPRO: $2.35 vs. XENE: $28.49)
Brand notoriety: SPRO and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SPRO: 4440% vs. XENE: 82%
Market capitalization -- SPRO: $139.78M vs. XENE: $2.43B
SPRO [@Biotechnology] is valued at $139.78M. XENE’s [@Biotechnology] market capitalization is $2.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $334.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SPRO’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • SPRO’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, both SPRO and XENE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPRO’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • SPRO’s TA Score: 5 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SPRO is a better buy in the short-term than XENE.

Price Growth

SPRO (@Biotechnology) experienced а +242.67% price change this week, while XENE (@Biotechnology) price change was -6.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

SPRO is expected to report earnings on Aug 07, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.43B) has a higher market cap than SPRO($140M). SPRO YTD gains are higher at: 128.155 vs. XENE (-27.321). SPRO has higher annual earnings (EBITDA): -2.45M vs. XENE (-276.74M). XENE has more cash in the bank: 627M vs. SPRO (76.3M). SPRO has less debt than XENE: SPRO (4.62M) vs XENE (9.02M). SPRO has higher revenues than XENE: SPRO (89.9M) vs XENE (0).
SPROXENESPRO / XENE
Capitalization140M2.43B6%
EBITDA-2.45M-276.74M1%
Gain YTD128.155-27.321-469%
P/E Ratio10.75N/A-
Revenue89.9M0-
Total Cash76.3M627M12%
Total Debt4.62M9.02M51%
FUNDAMENTALS RATINGS
SPRO vs XENE: Fundamental Ratings
SPRO
XENE
OUTLOOK RATING
1..100
395
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
10051
SMR RATING
1..100
7994
PRICE GROWTH RATING
1..100
8688
P/E GROWTH RATING
1..100
44
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (57) in the Pharmaceuticals Major industry is in the same range as XENE (75) in the Biotechnology industry. This means that SPRO’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (51) in the Biotechnology industry is somewhat better than the same rating for SPRO (100) in the Pharmaceuticals Major industry. This means that XENE’s stock grew somewhat faster than SPRO’s over the last 12 months.

SPRO's SMR Rating (79) in the Pharmaceuticals Major industry is in the same range as XENE (94) in the Biotechnology industry. This means that SPRO’s stock grew similarly to XENE’s over the last 12 months.

SPRO's Price Growth Rating (86) in the Pharmaceuticals Major industry is in the same range as XENE (88) in the Biotechnology industry. This means that SPRO’s stock grew similarly to XENE’s over the last 12 months.

SPRO's P/E Growth Rating (4) in the Pharmaceuticals Major industry is in the same range as XENE (4) in the Biotechnology industry. This means that SPRO’s stock grew similarly to XENE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SPROXENE
RSI
ODDS (%)
Bearish Trend 13 days ago
79%
Bullish Trend 13 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 13 days ago
79%
Bullish Trend 13 days ago
75%
Momentum
ODDS (%)
Bullish Trend 13 days ago
67%
Bearish Trend 13 days ago
84%
MACD
ODDS (%)
Bullish Trend 13 days ago
80%
Bearish Trend 13 days ago
56%
TrendWeek
ODDS (%)
Bullish Trend 13 days ago
73%
Bearish Trend 13 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 13 days ago
75%
Bearish Trend 13 days ago
77%
Advances
ODDS (%)
Bullish Trend 19 days ago
72%
Bullish Trend 21 days ago
73%
Declines
ODDS (%)
Bearish Trend about 1 month ago
90%
Bearish Trend 13 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 13 days ago
82%
Bullish Trend 13 days ago
76%
Aroon
ODDS (%)
N/A
Bullish Trend 13 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been closely correlated with CLGN. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if SPRO jumps, then CLGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
+244.57%
CLGN - SPRO
66%
Closely correlated
+76.17%
ASBP - SPRO
62%
Loosely correlated
+197.43%
ITOS - SPRO
35%
Loosely correlated
+17.94%
XENE - SPRO
32%
Poorly correlated
-3.29%
SYRE - SPRO
31%
Poorly correlated
+0.60%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with ATXS. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-3.29%
ATXS - XENE
54%
Loosely correlated
+6.85%
IDYA - XENE
54%
Loosely correlated
+0.72%
CRNX - XENE
53%
Loosely correlated
+1.39%
KYMR - XENE
51%
Loosely correlated
+2.35%
RCKT - XENE
50%
Loosely correlated
+6.44%
More